Drug intelligence / Profile preview

CT-2401

Development stage: Preclinical
Lead developer: Carisma Therapeutics Inc
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

CT-2401 is a preclinical-stage product candidate developed by Carisma Therapeutics for the treatment of liver fibrosis and autoimmune diseases. It utilizes a novel mRNA/lipid nanoparticle (LNP) approach, specifically TIM4 mRNA-loaded Kupffer cell tropic LNPs, to restore TIM4 expression. This mechanism aims to repair efferocytosis, a process crucial for clearing apoptotic cells, thereby dramatically reducing fibrosis.

Targets

TIMD4 (T-cell immunoglobulin and mucin domain-containing protein 4)

Beyond the preview

Go deeper on CT-2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-2401.

Explore the full profile